You are here: Industry Insights > BTK Inhibitor

News List

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology PharmaSources
April 18, 2024
The study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP.
Orelabrutinib: A Novel BTK inhibitor David Orchard-Webb
March 01, 2024
Orelabrutinib, developed by InnoCare Pharma, is an orally bioavailable, second-generation Bruton's tyrosine kinase (BTK) inhibitor.
The sales of the BTK inhibitor reached at least USD 11 billion worldwide in 2021 PharmaSources/Caicai
March 16, 2022
In today's new drug world, BTK inhibitor stands out as a member of chemical drugs in a context where biologics yield unusually brilliant results.
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021 PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
BeiGene's Zanubrutinib to Be Approved in China CPhI.CN
May 26, 2020
Zanubrutinib is one of the world's best-selling BTK inhibitor, with sales in 2019 reached 8.08 billion USD.
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
InnoCare Pharma announced 2023 interim results as of 30 June 2023 PharmaSources
September 04, 2023
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL PharmaSources
April 20, 2023
April 20, 2023，InnoCare Pharma announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma .
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology PharmaSources
February 07, 2023
American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH prnasia
December 14, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting...

Previous page 1 2 Next page